Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in ...

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.91, indicating a -6.19% shift from the previous trading day.

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

Recursion can validate hypotheses and design compounds much more quickly than drugmakers using traditional methods. And its cost to get to the point of filing an Investigational New Drug (IND) ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...

If language is what makes us human, what does it mean now that large language models have gained “metalinguistic” abilities?

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

Discover how Zero Knowledge Proof (ZKP) unlocks infinite scalability through recursive proofs. Join the whitelist soon to pre ...

Learn how Claude's ability to monitor its internal states could transform AI safety and provide insights into human brain ...